Press Release
Feb 2023: - Kite, a Gilead Company (NASDAQ: GILD), today announced the completion of the previously announced transaction to acquire Tmunity Therapeutics (Tmunity), a clinical...
gilead
Sept 2022: The European Commission (EC) has authorized Kite's CAR T-cell therapy Tecartus® (brexucabtagene autoleucel) for the treatment of adult patients 26 years of age and older with relapsed or r...
gilead